Senti Biosciences Holdings to spin off gene-circuit pipeline including SENTI-202 into NewCo for CVR worth up to $60 million
SNTI•Reorganization to split off gene-circuit pipeline
Senti Biosciences Holdings unveiled a reorganization to split off its Gene-Circuit pipeline, including AML therapy SENTI-202, into a new privately held biotech.
NewCo, controlled by affiliates of major investor Celadon, will acquire the assets in exchange for a contingent value right for equity holders.
CVR tied to SENTI-202 milestones and remaining company plans
The CVR offers up to $60 million over seven years, tied to SENTI-202 BLA filing, FDA approval, and commercial sales milestones.
The remaining company plans to seek new financing, refocusing on Regulator Dial-powered controllable genetic medicines and early-stage programs.
The transaction requires stockholder approval and customary closing conditions.
